{"id":"W2963860447","doi":"10.1016/j.jaip.2019.07.011","title":"Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population","year":2019,"lang":"en","type":"article","venue":"The Journal of Allergy and Clinical Immunology In Practice","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institute of Health Economics","funders":"Sage Therapeutics; Pearl Therapeutics; Valeant Pharmaceuticals International; AstraZeneca; Shire; Biogen; AbbVie; GlaxoSmithKline Australia; Sanofi; Regeneron Pharmaceuticals; Novartis; Pfizer; Novartis Pharmaceuticals Corporation; Pharmaceutical Research and Manufacturers of America Foundation; Boehringer Ingelheim","keywords":"Medicine; Discontinuation; Omalizumab; Asthma; Odds ratio; Odds; Pediatrics; Retrospective cohort study; Internal medicine; Logistic regression; Immunology; Immunoglobulin E","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002260058,0.0001429639,0.0003206469,0.000720623,0.000348742,0.0005296147,0.0002400333,0.0005114382,0.002001416],"category_scores_gemma":[0.001401736,0.0001756719,0.0005196842,0.001024917,0.0002143013,0.000529377,0.0003804372,0.0004340999,0.0002011426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000539878,"about_ca_system_score_gemma":0.0003089319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0123824,"about_ca_topic_score_gemma":0.01456613,"domain_scores_codex":[0.9995728,0.00008298389,0.00006853334,0.00008705151,0.00008253993,0.0001061131],"domain_scores_gemma":[0.999288,0.0001200042,0.0003983731,0.00002034277,0.00004437714,0.00012889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001605449,0.0000463278,0.9975753,0.000007356243,0.00004437343,0.00007179675,0.00006518492,0.00003849257,0.0002088148,0.00002831475,0.0001646839,0.001588793],"study_design_scores_gemma":[0.000005863589,0.00005519219,0.9991502,0.000006043606,0.00001597981,0.0001855919,0.0002574583,0.0001425329,0.00002945954,0.00001640214,0.0001327599,0.000002444354],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984408,0.000405148,0.0000234638,0.0001689729,0.000004256396,0.000004393088,0.0003413685,0.000002049028,0.0006094719],"genre_scores_gemma":[0.9993768,0.000145499,0.00002324413,0.00009699749,0.000009335291,0.000003959889,0.000217996,0.000001203306,0.0001250287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0123824,"threshold_uncertainty_score":0.02462065,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01248295531132643,"score_gpt":0.3190620458624283,"score_spread":0.3065790905511019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}